% | $
Quotes you view appear here for quick access.

Deckers Outdoor Corp. Message Board

ilygod 7 posts  |  Last Activity: Apr 2, 2015 8:20 PM Member since: Jan 29, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • GSK almost owns 32million shares; Baupost owns 21million shares; Iridian owns 12million shares...these guys are masters of M &A. One day THRX will be bought out for $24+

  • MorningNotes┬« SPO Notes
    DEAL PRICED Epizyme, Inc. SPO (EPZM:Nasdaq)
    Wednesday 03/18/2015 8:21 AM ET - MorningNotes
    6,000,000 shares @ $20.75, last sale $21.13. Up-sized from 4,750,000 shares. Managers: Leerink Swann, Cowen & Company, RBC Capital Markets
    CHATTER Epizyme, Inc. SPO (EPZM:Nasdaq)
    Tuesday 03/17/2015 2:30 PM ET - MorningNotes
    4,750,000 shares @ $22.07 Managers: Leerink Swann, Cowen & Company, RBC Capital Markets We hear demand is strong and like the pull back today. We have increased our rating to reflect this.

  • I see value here but Zack #1 Rank? Hummm

  • Leerink and Cowen already purchased the shares at $19.505 which is at a discount to the public. As for EPZM, they raised the money they needed. In hindsight, this seems like it was a smart move.

    On March 17, 2015, Epizyme, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the "Underwriters"), relating to an underwritten public offering of 6,000,000 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"). All of the Shares are being sold by the Company. The offering price to the public is $20.75 per share, and the Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $19.505 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 900,000 shares of Common Stock at the same price per share as the Shares.

    Sentiment: Hold

  • I think there's good science here. ARWR will be taken over for the Hep B portfolio. Race is likely against GILD...perhaps it is GILD that takes them out.

  • Reply to

    Resting today on low volume

    by xbob4 Feb 18, 2015 11:00 AM
    ilygod ilygod Mar 20, 2015 1:53 PM Flag

    Celgene already has a 12.5% stake in EPZM. Perhaps they just take them out here. That would be nice. Many options but with their nice cash cushion, I think EPZM controls their own destiny.

  • ilygod by ilygod Mar 20, 2015 1:44 PM Flag

    I wonder what happened to previous thoughts about acquisition from the likes of PFE. This could be a nice addition to their oncology product pipeline.

75.09+0.03(+0.04%)Apr 27 4:01 PMEDT